Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:activities |
NMDA receptor antagonist
dopamine agonist |
| gptkbp:appointed_by |
gptkb:beer
gptkb:item oral tablet |
| gptkbp:approves |
gptkb:1966
gptkb:FDA gptkb:EMA |
| gptkbp:brand |
gptkb:Gocovri
gptkb:Symmetrel |
| gptkbp:clinical_trial |
gptkb:psychologist
gptkb:influenza_A |
| gptkbp:contraindication |
severe renal impairment
lactation pregnancy category C concomitant use of certain medications history of seizures |
| gptkbp:discovered_by |
1940s
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
amantadine
|
| gptkbp:ingredients |
C10 H17 N
|
| gptkbp:interacts_with |
gptkb:beer
anticholinergic drugs CNS stimulants |
| gptkbp:is_atype_of |
N04 B D01
|
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
treatment of Parkinson's disease
treatment of influenza A |
| gptkbp:lifespan |
10 to 14 hours
|
| gptkbp:marketed_as |
various pharmaceutical companies
|
| gptkbp:metabolism |
minimal hepatic metabolism
|
| gptkbp:origin |
derived from adamantane
|
| gptkbp:pharmacokinetics |
oral bioavailability 90%.
|
| gptkbp:related_to |
gptkb:rimantadine
antiviral drugs dopamine |
| gptkbp:research_areas |
neurology
psychiatry infectious diseases neuropharmacology clinical pharmacology |
| gptkbp:side_effect |
anxiety
dizziness fatigue nausea confusion insomnia dry mouth skin rash hallucinations peripheral edema orthostatic hypotension |
| gptkbp:type_of |
665-66-7
|
| gptkbp:bfsParent |
gptkb:zanamivir
|
| gptkbp:bfsLayer |
5
|